These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17704517)

  • 21. In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time-kill assay.
    Pankey GA; Ashcraft DS
    Diagn Microbiol Infect Dis; 2009 Jul; 64(3):300-4. PubMed ID: 19501791
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Baseline in vitro activity of tigecycline among key bacterial pathogens exhibiting multidrug resistance.
    Draghi DC; Tench S; Dowzicky MJ; Sahm DF
    Chemotherapy; 2008; 54(2):91-100. PubMed ID: 18303257
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Colistin susceptibility testing by Etest and disk diffusion methods.
    Galani I; Kontopidou F; Souli M; Rekatsina PD; Koratzanis E; Deliolanis J; Giamarellou H
    Int J Antimicrob Agents; 2008 May; 31(5):434-9. PubMed ID: 18328674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tigecycline in-vitro susceptibility and antibiotics' fitness for gram-negative pathogens.
    Arya SC; Agarwal N
    Saudi Med J; 2008 Nov; 29(11):1558-60. PubMed ID: 18998000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative analysis of antimicrobial susceptibility among organisms from France, Germany, Italy, Spain and the UK as part of the tigecycline evaluation and surveillance trial.
    Rodloff AC; Leclercq R; Debbia EA; Cantón R; Oppenheim BA; Dowzicky MJ
    Clin Microbiol Infect; 2008 Apr; 14(4):307-14. PubMed ID: 18261126
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activity of tigecycline against resistant micro-organisms isolated from burn patients.
    Timurkaynak F; Arslan H; Azap OK; Senger SS; Başaran O; Karaman SO; Haberal M
    Burns; 2008 Nov; 34(7):1033-6. PubMed ID: 18539397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
    Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Enterobacteriaceae.
    Lu CT; Chuang YC; Sun W; Liu YC; Cheng YJ; Lu PL; Chen CM; Hsu GJ; Jang TN; Lee CM; Chiang PC; Shi ZY; Wang LS; Kung HC; Lin HC; Liao CH; Liu JW; Huang CH; Tsao SM; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S179-83. PubMed ID: 19013351
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Methodological agreement on the in vitro activity of ceftaroline against cefotaxime-susceptible and -resistant pneumococci.
    Livermore DM; Warner M; Mushtaq S
    Int J Antimicrob Agents; 2014 Feb; 43(2):131-4. PubMed ID: 24361355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of in vitro activities of tigecycline with other antimicrobial agents against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in two university hospitals in Istanbul, Turkey.
    Gonullu N; Catal F; Kucukbasmaci O; Ozdemir S; Torun MM; Berkiten R
    Chemotherapy; 2009; 55(3):161-7. PubMed ID: 19390189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tigecycline and intravenous fosfomycin zone breakpoints equivalent to the EUCAST MIC criteria for Enterobacteriaceae.
    Pasteran F; Lucero C; Rapoport M; Guerriero L; Barreiro I; Albornoz E; Veliz O; Corso A
    J Infect Dev Ctries; 2012 May; 6(5):452-6. PubMed ID: 22610713
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro susceptibility of tigecycline against multidrug-resistant gram-negative strains: Etest versus agar dilution.
    Özkök S; Togan T; Yesilkaya A; Timurkaynak F; Azap ÖK; Arslan H
    Chemotherapy; 2014; 60(3):151-6. PubMed ID: 25791941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility testing challenges with ceftaroline, MRSA and a 1 mg/L breakpoint.
    Livermore DM; Mushtaq S; Warner M; James D; Woodford N
    J Antimicrob Chemother; 2015 Dec; 70(12):3259-66. PubMed ID: 26318188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Calcium-supplemented daptomycin Etest strips for susceptibility testing on Iso-Sensitest agar.
    Johnson AP; Mushtaq S; Warner M; Livermore DM
    J Antimicrob Chemother; 2004 May; 53(5):860-2. PubMed ID: 15056637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Comparison of the results of the Etest and the method for determining minimum inhibitory concentrations in solid media for penicillin G, amoxicillin, and cefotaxime for S. pneumoniae. A multicenter study].
    Clavier B; Perrier-Gros-Claude JD; Foissaud V; Dumas M; Aubert G; Barbé G; Bland S; Boucaud Maitre Y; Boyer M; Chomarat M; Clergeau P; Delubac F; Févre D; Fuhrmann C; Gravagnat B; Letouzey MN; Mandjee A; Martelet P; Meley R; Reverdy ME; Ros A; Roure C; Sabot O; Tixier A; Thierry J
    Pathol Biol (Paris); 1998 Jun; 46(6):369-74. PubMed ID: 9769863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. False extended-spectrum beta-lactamase detection in Acinetobacter spp. due to intrinsic susceptibility to clavulanic acid.
    Beceiro A; Fernández-Cuenca F; Ribera A; Martínez-Martínez L; Pascual A; Vila J; Rodríguez-Baño J; Cisneros JM; Pachón J; Bou G;
    J Antimicrob Chemother; 2008 Feb; 61(2):301-8. PubMed ID: 18065824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The correlation between the MICs deduced from Showa disk method and the MICs determined by micro-dilution method].
    Moroizumi S; Kasitani F; Isikawa M; Iwata M; Ohno A; Yamaguchi K
    Rinsho Byori; 1994 Oct; 42(10):1062-8. PubMed ID: 7996716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antimicrobial susceptibility among organisms from the Asia/Pacific Rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline.
    Reinert RR; Low DE; Rossi F; Zhang X; Wattal C; Dowzicky MJ
    J Antimicrob Chemother; 2007 Nov; 60(5):1018-29. PubMed ID: 17855724
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tigecycline (GAR-936) activity against Streptococcus gallolyticus (bovis) and viridans group streptococci.
    Moet GJ; Dowzicky MJ; Jones RN
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):333-6. PubMed ID: 16989974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Zone breakpoints, by the CLSI disc method, for 15 μg tigecycline discs corresponding to EUCAST MIC breakpoints.
    Hope R; Pllana T; James D; Warner M; Livermore DM
    J Antimicrob Chemother; 2010 Oct; 65(10):2262-4. PubMed ID: 20685753
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.